

Online Expert Poster Review and Discussion  
 ARV Therapies and Therapeutic Strategies  
*Reporting From*  
 The 19th Conference on Retroviruses  
 and Opportunistic Infections (CROI)  
 JOINTLY SPONSORED BY THE POSTGRADUATE INSTITUTE FOR MEDICINE AND VIRALeD, LLC

## GS-7977 + Ribavirin in HCV Genotype 1 Null Responders: Results from the ELECTRON Trial

E. Gane,<sup>1</sup> C. Stedman,<sup>2</sup> J. Anderson,<sup>3</sup> R. Hyland,<sup>3</sup> R. Hindes,<sup>3</sup>  
 W. Symonds,<sup>3</sup> M.M. Berrey<sup>4</sup>


<sup>1</sup>Auckland City Hospital, New Zealand, <sup>2</sup>Christchurch Hospital, Christchurch, New Zealand,  
<sup>3</sup>Gilead Sciences, Inc., Foster City, California, <sup>4</sup>Independent Consultant

Abstract 54LB




## ELECTRON Study Design for HCV Genotype 1

- To evaluate the antiviral activity of 12 weeks GS-7797 + RBV in genotype 1 patients who were either:
  - Prior null responder (<2 log<sub>10</sub> reduction in HCV RNA at week 12 of a Peg/RBV regimen)
  - Treatment-naïve




- RBV dosing in all arms, independent of HCV genotype, was 1000 mg for patients <75 kg and 1200 mg for those ≥75 kg

# Rapid Viral Suppression in Prior Null and Treatment-Naïve Genotype 1 Patients



Gane E, et al. 19<sup>th</sup> CROI; Seattle, WA; March 5-8, 2012; Abst. 54LB.

# Null Responders: Individual Patient HCV RNA Level



n/N <LOD    7/10    10/10    9/9    9/9    9/9    9/9    4/9    1/9

Gane E, et al. 19<sup>th</sup> CROI; Seattle, WA; March 5-8, 2012; Abst. 54LB.